| LRP4 Protein | |
|---|---|
| Protein Name | Low Density Lipoprotein Receptor-Related Protein 4 |
| Gene | LRP4 |
| UniProt | Q9NZU6 |
| Molecular Weight | ~215 kDa |
| Length | 1,898 amino acids |
| Cellular Location | Plasma membrane, Synapses |
| Expression | Brain, Muscle, Kidney, Lung, Heart |
| Aliases | LRP4, MEGF7 |
LRP4 (Low Density Lipoprotein Receptor-Related Protein 4) is a member of the LDLR family that serves as a key co-receptor for neuromuscular junction (NMJ) formation and synaptic development. Unlike its relatives LRP1 and LRP2, LRP4 has specialized functions in orchestrating postsynaptic machinery at the neuromuscular junction and in select brain regions. Mutations in LRP4 cause congenital myasthenic syndromes andcenefal dysplasia, and dysregulated LRP4 signaling has been implicated in neurodegenerative diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The receptor interacts with agrin, a heparan sulfate proteoglycan released from motor neuron terminals, to cluster acetylcholine receptors (AChRs) at the motor endplate.
LRP4 is a type I transmembrane receptor with a distinctive domain organization:
The extracellular region of LRP4 binds to:
LRP4's best-characterized function is as the postsynaptic receptor for agrin, a massive heparan sulfate proteoglycan released from motor neuron terminals. The LRP4-agrin interaction initiates a cascade of events essential for NMJ formation:
Beyond the NMJ, LRP4 is expressed in select brain regions, particularly in the hippocampus and cortex, where it participates in:
LRP4 also functions as a receptor for sclerostin, a bone formation inhibitor produced by osteocytes. The LRP4-sclerostin interaction inhibits the Wnt/β-catenin pathway in osteoblasts, regulating bone mass.
LRP4 has been increasingly implicated in Alzheimer's disease pathogenesis:
Synaptic Function: Given LRP4's role in excitatory synapse formation and maintenance, its dysregulation may contribute to synaptic loss, a hallmark of AD.
Amyloid Pathology: LRP4 interacts with amyloid precursor protein (APP) and may influence amyloid-beta production or clearance. Some studies suggest LRP4 can modulate γ-secretase activity.
Tau Pathology: LRP4 expression is altered in AD brains, and the receptor may be involved in tau phosphorylation pathways.
Genetic Association: Polymorphisms in the LRP4 gene have been associated with increased AD risk in some populations.
LRP4 has emerged as a player in ALS pathogenesis:
NMJ Dysfunction: LRP4 is critical for neuromuscular junction integrity. Disruption of LRP4 signaling may contribute to denervation in ALS.
Motor Neuron Vulnerability: LRP4 expression is reduced in ALS patient spinal cord and in mouse models, potentially making motor neurons more vulnerable to degeneration.
Aggregation: LRP4 has been reported to co-aggregate with TDP-43 in some ALS cases, though this is less well-characterized than other ALS proteins.
Autoimmune Components: Autoantibodies against LRP4 have been detected in some ALS patients, suggesting potential immune-mediated mechanisms.
While not a neurodegenerative disease per se, LRP4 autoantibodies have been identified in a subset of myasthenia gravis patients, particularly those with mild disease. This reinforces the importance of LRP4 in neuromuscular junction function.
LRP4 Agonists: Small molecules or peptides that enhance LRP4 signaling could potentially stabilize NMJs in ALS or improve synaptic function in AD.
Antibody Therapeutics: Monoclonal antibodies targeting LRP4 are being explored for both myasthenia gravis and potential neuroprotective applications.
Gene Therapy: AAV vectors carrying LRP4 are being investigated for ALS gene therapy approaches.
Biomarker Potential: Soluble LRP4 (sLRP4) in serum or CSF may serve as a biomarker for synaptic integrity in neurodegenerative diseases.
| Protein/Pathway | Interaction Type | Functional Consequence |
|---|---|---|
| Agrin | Receptor-ligand | AChR clustering, NMJ formation |
| MuSK | Kinase interaction | Synaptic differentiation |
| Rapsyn | Scaffold | AChR clustering |
| Wnt ligands | Receptor-cofactor | Wnt/β-catenin signaling |
| APP | Potential interaction | Amyloid processing |
| Sclerostin | Receptor-ligand | Bone metabolism |